Analysis: Entering the age of the $1 million medicine

Comments (4)
Iconicologist wrote:

Not sure how you can conclude “the only snag is the price” when you fail to mention or discuss potential side effects.

Jan 04, 2013 8:48pm EST  --  Report as abuse
americanguy wrote:

But the wealthy will need the cure, so spend all the time and money possible to develop cures for a disease that only the wealthy can afford or have.
That’s the way it is now.
The gods of wealth look down on us and laugh.

Jan 04, 2013 10:02pm EST  --  Report as abuse
SanPa wrote:

In olden days v.v. pre-Reaganomics, universities were the source for orphan drugs. One example was ALG, a very effective immunosuppressive composition used to ameliorate transplant rejection. Ah, but thanks to Reagan’s priority shifts in research funding and his emphasis on privatization, work that lead to treatments costing $10′s of thousands now come from private sources for over a million. And as an added bonus, the big discoveries of tomorrow will come from China, where basic research is valued, and not from the US where lawmakers have contempt for science.

Jan 04, 2013 11:30pm EST  --  Report as abuse
123456951 wrote:

A few years ago a relative of mine got cancer. The cost of surgery was $60,000 for an 8 hour surgery. Amazingly, because of insurance, we did not pay anything; but get this: the insurance company, because it had a deal with the hospital, only paid the hospital $15,000. So, we paid nothing, and the hospital got $15,000 for a $60,000 surgery. But this was the really amazing part: Treatment also involved about $100,000 in drug costs. The insurance company paid practically every cent of it. We paid very little. The point to me was how powerful the drug companies seemed to be compared to the hospital in getting paid. Something HAS to give here; and in a huge way. In this country we somehow need to elect politicians who will not listen to ANY special interests.

Jan 05, 2013 3:20am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.